



16711 U.S. PTO

Please type a plus sign (+) inside this box ☐

Attorney Docket **P3121R1C1**
PATENT

03945 U.S. PTO
10/700992



EV 351932707: Express Mail Number

November 3, 2001: Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BOX PATENT APPLICATION
Assistant Commissioner of Patents
Washington, D.C. 20231

NON-PROVISIONAL APPLICATION TRANSMITTAL UNDER 37 CFR 1.53(b)

Transmitted herewith for filing is a non-provisional patent application:

Inventor(s) (or Application "Identifier"):

**Audrey Goddard
Paul J. Godowski
Austin L. Gurney
Colin K. Watanabe
William I. Wood**

Title: **NOVEL POLYPEPTIDES HAVING SEQUENCE SIMILARITY TO CYTOKINE RECEPTORS
AND NUCLEIC ACIDS ENCODING THE SAME**

1. Type of Application

- ☐ This application is for an original, non-provisional application.
- ☐ This is a non-provisional application claiming priority to provisional application no. __, filed ____, the entire disclosure of which is hereby incorporated by reference.
- ☒ This is a ☐ continuation-in-part ☒ continuation ☐ divisional application claiming priority under 35 U.S.C. §120 of U.S. Application Serial No. 09/964,994 filed September 26, 2001, which is a continuation-in-part of, and claims priority under 35 U.S.C. §120 of U.S. Application Serial No. 09/941,992 filed August 28, 2001, which is a continuation of, and claims priority under 35 U.S.C. §119 (a)-(d) to PCT Application No. PCT/US00/08439 filed March 30, 2000, and where U.S. Application Serial No. 09/941,992 is also a continuation-in-part of, and claims priority under 35 U.S.C. §119 (a)-(d) to PCT Application No. PCT/US01/06520 filed February 28, 2001, which claims priority under 35 U.S.C. §119 (e) to U.S. Provisional Application Serial No. 60/191,105 filed March 21, 2000, the entire disclosures of which are hereby expressly incorporated by reference.

**2. Papers Enclosed Which Are Required For Filing Date Under 37 CFR 1.53(b)
(Non-provisional)**

81 pages of specification
5 pages of claims
1 page(s) of abstract
4 sheet(s) of drawings
[X] formal ☐ informal

3. Declaration r Oath

☐ *(for new and CIP applications; also for Cont./Div. where inventor(s) are being added)*
An unassigned declaration of the inventors is enclosed. A signed declaration of the inventors will follow.

☒ *(for Cont./Div. where inventorship is the same or inventor(s) being deleted)*
A copy of the executed declaration/oath filed in the prior application is enclosed (37 CFR 1.63(d)).

☐ *(for Cont./Div. where inventor(s) being deleted)*
A signed statement is attached deleting inventor(s) named in the prior application (see 37 CFR 1.63(d)(2) and 1.33(b)).

4. Assignment

☐ *(for new and CIP applications)*
An Assignment of the invention to GENENTECH, INC. ☐ is enclosed with attached Recordation Form Cover Sheet ☒ will follow.

☒ *(for cont./div.)*
The prior application is assigned of record to Genentech, Inc.

5. Amendments (for continuation and divisional applications)

☐ Cancel in this application original claims __ of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)

☒ A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)

6. Fee Calculation (37 CFR 1.16)

The fee has been calculated as follows:

This document has been prepared as follows:

CLAIMS FOR FEE CALCULATION					
Number Filed		Number Extra		Rate	Basic Fee 37 CFR 1.16(a)
					\$770.00
Total Claims	52	- 20 =	32	X \$18.00	\$576.00
Independent Claims	22	- 3 =	19	X \$86.00	\$1,634.00
<u>X</u> Multiple dependent claim(s), if any				+ \$290.00	\$290.00
Filing Fee Calculation					\$3,270.00

7. Method of Payment of Fees

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$3,270.00. **A duplicate copy of this transmittal is enclosed.**

8. Authorization to Charge Additional Fees

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. **A duplicate copy of this sheet is enclosed.**

9. Additional Papers Enclosed

- ☐ Information Disclosure Statement (37 CFR §1.98) w/ PTO-1449 and citations
☒ Submission of "Sequence Listing", certificate re: sequence listing, and/or amendment pertaining thereto for biological invention containing nucleotide and/or amino acid sequence.
☐ A new Power of Attorney or authorization of agent.
☐ Other:

10. Maintenance of Copendency of Prior Application (for continuation and divisional applications)

[This item must be completed and the necessary papers filed in the prior application if the period set in the prior application has run]

- _____ A petition, fee and/or response has been filed to extend the term in the pending prior application until
 _____ A copy of the petition for extension of time in the **prior** application is attached.


11. Correspondence Address:

X Address all future communications to:

Attn: Elizabeth M. Barnes

Respectfully submitted,
GENENTECH, INC.

Date: November 3, 2003

By: 
Elizabeth M. Barnes
Reg. No. 65,059
Telephone No. (650) 225-4563

09157

PATENT TRADEMARK OFFICE